Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OSIMERTINIB MESYLATE vs CLOFARABINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that selectively inhibits EGFR exon 19 deletion and L858R substitution mutations, as well as T790M resistance mutations, with less activity against wild-type EGFR.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
FDA-approved: Adjuvant therapy after tumor resection in patients with EGFR exon 19 deletions or exon 21 L858R mutations; first-line treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations; metastatic NSCLC with EGFR T790M mutation after progression on EGFR TKI therapy.,Off-label: Treatment of leptomeningeal carcinomatosis from EGFR-mutant NSCLC.
Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
80 mg orally once daily, with or without food.
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
Terminal elimination half-life is approximately 48 hours (range 36-60 h) based on population pharmacokinetic analysis, supporting once-daily dosing.
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Metabolized primarily by CYP3A4; minor contributions from CYP3A5 and CYP1A1. Forms active metabolites (AZ5104 and AZ7550) that contribute to clinical activity.
Hepatic; primarily metabolized by deamination via cytidine deaminase to 6-ketoclofarabine, a major metabolite. Also undergoes phosphorylation intracellularly. CYP450 involvement is minimal.
Osimertinib is eliminated primarily via feces (67.8%, with 1.2% as unchanged drug) and urine (13.8%, with 0.8% as unchanged drug). The remainder is recovered as metabolites.
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
Approximately 95% bound to human plasma proteins, primarily to albumin and alpha-1-acid glycoprotein.
47% bound to plasma proteins (primarily albumin)
Apparent volume of distribution (Vd/F) is approximately 956 L, suggesting extensive tissue distribution. Not expressed per kg, but corresponds to a very large Vd (approximately 13.7 L/kg for a 70 kg person).
Vd: 14.6 L/kg (range 10-20 L/kg); indicates extensive extravascular distribution and tissue binding
Oral bioavailability is estimated to be approximately 70% based on mass balance and absorption studies. Absorption is unaffected by food.
IV: 100% (only IV route); oral: not approved
No dose adjustment required for GFR >=15 m L/min; insufficient data for GFR <15 m L/min or dialysis.
Clcr ≥ 60 m L/min: no adjustment; Clcr 30-59 m L/min: reduce dose to 39 mg/m^2; Clcr < 30 m L/min: not recommended (no data).
Child-Pugh A: no adjustment; Child-Pugh B: 80 mg once daily; Child-Pugh C: not recommended due to lack of data.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25% (monitor toxicity); Child-Pugh C: not recommended (no data).
Safety and efficacy not established in pediatric patients.
52 mg/m^2 intravenously over 2 hours daily for 5 days every 28 days (same as adult dosing per body surface area; safety and efficacy established in pediatric patients 1 year and older).
No specific dose adjustment; clinical studies included patients >=65 years with no overall differences in safety or efficacy.
No specific dose adjustment based solely on age; monitor renal function closely due to increased risk of nephrotoxicity; use same dosing as adults with renal adjustment as per GFR.
Black Box Warning: Interstitial lung disease (ILD)/pneumonitis, which can be fatal. Monitor for new or worsening respiratory symptoms. Withhold or permanently discontinue based on severity.
Clofarabine causes severe bone marrow suppression, including neutropenia, anemia, thrombocytopenia, and increased risk of infection. Hemorrhage and severe infections have been reported. Monitor blood counts regularly.
Interstitial lung disease (ILD)/pneumonitis: Monitor pulmonary symptoms; withhold or permanently discontinue based on severity.,QTc interval prolongation: Monitor electrolytes and ECG in patients with risk factors; withhold or permanently discontinue for QTc >500 ms.,Cardiomyopathy: Assess left ventricular ejection fraction (LVEF) before and during treatment; withhold for symptomatic congestive heart failure.,Keratitis: Evaluate for signs of keratitis, especially in patients with prior ocular conditions.,Fetal harm: Can cause fetal harm; advise females of reproductive potential of effective contraception during and for 6 weeks after treatment.,Embryo-fetal toxicity: Verify pregnancy status before initiation.
1) Myelosuppression: monitor CBCs; dose adjustment may be needed. 2) Infections: increased susceptibility. 3) Hemorrhagic cystitis: may occur; manage with hydration and monitoring. 4) Hepatic toxicity: monitor liver function tests; dose reduction in hepatic impairment. 5) Renal toxicity: monitor renal function; dose adjustment for creatinine clearance <60 m L/min. 6) Tumor lysis syndrome: hydrate and use prophylactic allopurinol. 7) Systemic inflammatory response syndrome (SIRS): monitor for signs; discontinue if occurs.
None (no absolute contraindications listed in prescribing information).
Hypersensitivity to clofarabine or any component of the formulation; severe hepatic impairment (Child-Pugh class C); severe renal impairment (creatinine clearance <30 m L/min).
Avoid grapefruit and grapefruit juice, Seville oranges, and star fruit due to potential CYP3A4 inhibition. No other dietary restrictions.
Grapefruit and grapefruit juice may affect liver enzymes and should be avoided. No specific food restrictions, but avoid alcohol due to potential hepatotoxicity. Maintain adequate hydration; no other known food interactions.
Based on its mechanism of action (EGFR tyrosine kinase inhibition) and animal studies, osimertinib is expected to cause fetal harm when administered to a pregnant woman. In animal reproduction studies, osimertinib was embryotoxic and teratogenic at exposures below the recommended human dose. First trimester exposure poses the highest risk for major malformations. Second and third trimester exposure may cause fetal growth retardation and oligohydramnios. Use is contraindicated in pregnancy unless no alternative therapy exists.
Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malformations including neural tube defects, skeletal anomalies, and cardiovascular defects. Second and third trimester exposure may cause fetal myelosuppression, intrauterine growth restriction, and premature delivery.
It is unknown whether osimertinib or its metabolites are excreted in human milk. However, due to the potential for serious adverse reactions in breastfed infants (e.g., EGFR inhibition affecting neonatal growth and development), breastfeeding is not recommended during treatment and for at least 3 weeks after the last dose. No human milk-to-plasma (M/P) ratio data are available.
It is unknown whether clofarabine is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is not available.
No specific dose adjustments for pregnancy have been established due to lack of human data. Pregnancy-induced changes in drug absorption, distribution, metabolism, and excretion (e.g., increased renal blood flow, altered CYP3A activity) may alter osimertinib exposure; however, therapeutic drug monitoring is not routinely recommended. The manufacturer advises avoiding use in pregnancy unless benefit outweighs risk; if used, consider monitoring for toxicity due to potential altered pharmacokinetics.
No specific pharmacokinetic studies have been conducted in pregnant women. Dose adjustments based on pregnancy-induced physiologic changes (increased plasma volume, renal clearance) are not established. Use with caution; the lowest effective dose based on tolerability and clinical response is recommended. Close monitoring for toxicity is essential.
Osimertinib is a third-generation EGFR-TKI selective for both sensitizing and T790M resistance mutations. Monitor for interstitial lung disease (ILD) and QTc prolongation. Dose reduction or interruption may be needed for adverse reactions. Avoid concurrent use with strong CYP3A4 inducers.
Clofarabine is a purine nucleoside antimetabolite used primarily in pediatric relapsed or refractory acute lymphoblastic leukemia (ALL). It is associated with significant myelosuppression; monitor absolute neutrophil count and platelets closely. Capillary leak syndrome and systemic inflammatory response syndrome (SIRS) are rare but serious adverse effects; consider prophylactic corticosteroids. Hepatic veno-occlusive disease (VOD) has been reported, especially in patients with prior stem cell transplant. Administer with adequate hydration and monitor for tumor lysis syndrome.
Take exactly as prescribed, once daily with or without food.,Avoid grapefruit, grapefruit juice, Seville oranges, and star fruit during treatment.,Report new or worsening respiratory symptoms (cough, dyspnea, fever) immediately.,Notify your doctor if you experience palpitations, dizziness, or fainting (QT prolongation risk).,Use effective contraception during treatment and for 6 weeks after the last dose.,Breastfeeding is not recommended while on this medication.
Clofarabine is a chemotherapy drug that may lower your blood cell counts, increasing risk of infection, bleeding, and fatigue.,Report any signs of infection (fever, chills, sore throat), unusual bleeding or bruising, or shortness of breath immediately.,Drink plenty of fluids (8-10 glasses per day) to prevent kidney problems and tumor lysis syndrome.,Avoid live vaccines and close contact with people who have recently received oral polio vaccine.,Use effective contraception during treatment and for at least 6 months after the last dose.,Do not breastfeed while taking clofarabine.,You may experience nausea, vomiting, or diarrhea; your doctor can prescribe medications to manage these symptoms.
"Metronidazole is a known inhibitor of CYP3A4, the primary enzyme responsible for metabolizing Osimertinib. Coadministration increases Osimertinib AUC by approximately 30-60%, leading to elevated plasma concentrations that may potentiate adverse effects such as QTc prolongation, interstitial lung disease, and diarrhea. Clinicians should monitor for signs of Osimertinib toxicity and consider dose reduction if concurrent use is unavoidable."
"Osimertinib, a tyrosine kinase inhibitor used in non-small cell lung cancer, can inhibit P-glycoprotein (P-gp) transport in the gastrointestinal tract and kidneys, leading to increased absorption and reduced renal clearance of digoxin. This elevation in serum digoxin concentration heightens the risk of digoxin toxicity, including cardiac arrhythmias (e.g., bradycardia, atrial tachycardia with block) and gastrointestinal symptoms such as nausea and vomiting. Clinical monitoring for digoxin toxicity is warranted, especially when initiating or adjusting osimertinib therapy."
"Osimertinib, a potent EGFR tyrosine kinase inhibitor, significantly reduces the serum concentration of rasagiline, a monoamine oxidase B (MAO-B) inhibitor used in Parkinson's disease. This interaction is primarily mediated through Osimertinib's induction of CYP1A2, the major enzyme responsible for rasagiline metabolism, leading to enhanced clearance and subtherapeutic rasagiline levels. Clinically, this may result in reduced efficacy of rasagiline, potentially worsening Parkinsonian symptoms and requiring dose adjustments."
"Clofarabine, a purine nucleoside antimetabolite used in hematologic malignancies, may reduce the metabolism of Eltrombopag, a thrombopoietin receptor agonist, via inhibition of UDP-glucuronosyltransferase (UGT) enzymes, particularly UGT1A1 and UGT1A3. This leads to increased systemic exposure of Eltrombopag, potentially elevating the risk of hepatotoxicity (e.g., elevated liver enzymes) and other adverse effects such as thrombosis. Clinical outcomes may include exacerbated liver injury, which is particularly concerning in patients with pre-existing hepatic impairment or those receiving other hepatotoxic agents."
"Concurrent use of clofarabine and mecamylamine may synergistically increase the risk of severe hypotension and syncope. Clofarabine is a purine nucleoside analog that can cause capillary leak syndrome and hypotension, while mecamylamine is a ganglionic blocker that inhibits sympathetic outflow, leading to orthostatic hypotension. The combined hypotensive effects may result in profound blood pressure reduction, dizziness, and potential falls, particularly in patients with impaired cardiovascular function."
"The combination of clofarabine and nifedipine may increase the risk of cardiotoxicity, particularly QT interval prolongation and left ventricular dysfunction. Clofarabine has been associated with pericardial effusion and cardiac tamponade, while nifedipine, a calcium channel blocker, can cause hypotension and reflex tachycardia, potentially compounding hemodynamic stress in patients with compromised cardiac function. Clinical outcomes may include arrhythmias, heart failure exacerbation, or sudden cardiac death, especially in patients with preexisting cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OSIMERTINIB MESYLATE vs CLOFARABINE, answered by our medical review team.
OSIMERTINIB MESYLATE is a Antineoplastic Agent that works by Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that selectively inhibits EGFR exon 19 deletion and L858R substitution mutations, as well as T790M resistance mutations, with less activity against wild-type EGFR.. CLOFARABINE is a Antineoplastic Agent that works by Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OSIMERTINIB MESYLATE and CLOFARABINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OSIMERTINIB MESYLATE is: 80 mg orally once daily, with or without food.. The standard adult dose of CLOFARABINE is: 52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OSIMERTINIB MESYLATE and CLOFARABINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OSIMERTINIB MESYLATE is classified as Category C. Based on its mechanism of action (EGFR tyrosine kinase inhibition) and animal studies, osimertinib is expected to cause fetal harm when administered to a pregnant woman. In animal . CLOFARABINE is classified as Category C. Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malf. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.